Revolutionizing rheumatic heart disease prevention: the potential of high-dose subcutaneous benzathine penicillin G: a narrative review
DOI:
https://doi.org/10.18203/issn.2454-2156.IntJSciRep20250061Keywords:
Rheumatic heart disease , Acute rheumatic fever , Benzathine penicillin G, Subcutaneous injection, Prophylaxis, PharmacologyAbstract
Rheumatic heart disease (RHD) is a severe, chronic condition arising from acute rheumatic fever (ARF), a complication of untreated group A - Streptococcus infections. RHD results in progressive damage to the heart valves, leading to significant morbidity and mortality. While RHD has declined in high-income countries due to effective prophylaxis, it remains a major health issue in developing regions. Approximately 15 million people worldwide are affected by RHD, impacting quality of life and healthcare systems. This narrative review evaluates the efficacy and safety of high-dose subcutaneous benzathine penicillin G (BPG) injections as a preventive strategy for RHD. Traditionally administered intramuscularly, the review explores the subcutaneous route’s benefits. Subcutaneous BPG is effective in preventing ARF recurrences and managing RHD progression. It maintains therapeutic penicillin levels over extended periods, potentially reducing injection frequency. This method is associated with less pain and improved patient adherence compared to intramuscular injections. However, subcutaneous BPG administration has challenges. Adverse effects, such as allergic reactions and anaphylaxis, though infrequent, require careful management. Consistent drug supply is also essential. Future research should explore innovative delivery methods, such as implantable devices or transdermal systems, to further improve patient outcomes. In conclusion, high-dose subcutaneous BPG injections offer a promising option for RHD prophylaxis, combining efficacy with a favorable safety profile. Addressing administration and side effect challenges is crucial for optimizing treatment effectiveness.
Metrics
References
Oliver J, Bennett J, Thomas S, Zhang J, Pierse N, Moreland NJ, et al. Preceding group A Streptococcus skin and throat infections are individually associated with acute rheumatic fever: evidence from New Zealand. BMJ Glob Health. 2021;6:e007038. DOI: https://doi.org/10.1136/bmjgh-2021-007038
Kado J, Salman S, Hla TK, Enkel S, Henderson R, Hand RM, et al. Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic study. Antimicrob Agents Chemother. 2023;67:e00962-23. DOI: https://doi.org/10.1128/aac.00962-23
Cooper J, Enkel SL, Moodley D, Dobinson H, Andersen E, Kado JH, et al. "Hurts less, lasts longer"; a qualitative study on experiences of young people receiving high-dose subcutaneous injections of benzathine penicillin G to prevent rheumatic heart disease in New Zealand. PLoS One. 2024;19(5):e0302493. DOI: https://doi.org/10.1371/journal.pone.0302493
Liu M, Lu L, Sun R, Zheng Y, Zhang P. Rheumatic Heart Disease: Causes, Symptoms, and Treatments. Cell Biochem Biophys. 2015;72(3):861-3. DOI: https://doi.org/10.1007/s12013-015-0552-5
Seckeler, MD, Hoke, TR. The worldwide epidemiology of acute rheumatic fever and rheumatic heart disease. Clin Epidemiol. 2011;3:67-84. DOI: https://doi.org/10.2147/CLEP.S12977
Oben G, Duncanson M, Adams J, Satyanand T. State of child health: acute rheumatic fever in Aotearoa New Zealand. J Roy Soc N Z. 2023;53(5):631-40. DOI: https://doi.org/10.1080/03036758.2022.2113102
Roy S, Banik S. Current prevalence trend of rheumatic heart disease in South Asia: a systematic review. J Public Health (Berl). 2022;30:2483-90. DOI: https://doi.org/10.1007/s10389-021-01578-y
Rwebembera J, Beaton AZ, de Loizaga SR, Rocha RTL, Doreen N, Ssinabulya I, et al. The Global Impact of Rheumatic Heart Disease. Curr Cardiol Rep. 2021;23(11):160. DOI: https://doi.org/10.1007/s11886-021-01592-2
Mekonen KK, Yismaw MB, Abiye AA, Tadesse TA. Adherence to Benzathine Penicillin G Secondary Prophylaxis and Its Determinants in Patients with Rheumatic Heart Disease at a Cardiac Center of an Ethiopian Tertiary Care Teaching Hospital. Patient Prefer Adherence. 2020;14:343-52.
Ralph AP, de Dassel JL, Kirby A, Read C, Mitchell AG, Maguire GP, et al. Improving Delivery of Secondary Prophylaxis for Rheumatic Heart Disease in a High-Burden Setting: Outcome of a Stepped-Wedge, Community, Randomized Trial. J Am Heart Assoc. 2018;7(14):e009308. DOI: https://doi.org/10.1161/JAHA.118.009308
Holland JV, Hardie K, de Dassel J, Ralph AP. Rheumatic Heart Disease Prophylaxis in Older Patients: A Register-Based Audit of Adherence to Guidelines. Open Forum Infect Dis. 2018;5(6):ofy125. DOI: https://doi.org/10.1093/ofid/ofy125
Hand RM, Salman S, Newall N, Vine J, Page-Sharp M, Bowen AC, et al. A population pharmacokinetic study of benzathine benzylpenicillin G administration in children and adolescents with rheumatic heart disease: new insights for improved secondary prophylaxis strategies. J Antimicrob Chemother. 2019;74:1984-91. DOI: https://doi.org/10.1093/jac/dkz076
Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice Guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014;59:e10-52. DOI: https://doi.org/10.1093/cid/ciu296
Cheng G, Dai M, Ahmed S, Hao H, Wang X, Yuan Z. Antimicrobial drugs in fighting against antimicrobial resistance. Front Microbiol. 2016;7:470. DOI: https://doi.org/10.3389/fmicb.2016.00470
Wilke MS, Lovering AL, Strynadka NC. β-Lactam antibiotic resistance: a current structural perspective. Curr Opin Microbiol. 2005;8:525-33. DOI: https://doi.org/10.1016/j.mib.2005.08.016
RHD Australia, National Heart Foundation of Australia, Cardiac Society of Australia and New Zealand. Australian Guideline for Prevention, Diagnosis and Management of Acute Rheumatic Fever and Rheumatic Heart Disease. 2nd Edition. Darwin (Australia): Menzies School of Health Research. 2012.
Manyemba J, Mayosi BM. Penicillin for secondary prevention of rheumatic fever. Cochrane Database Syst Rev. 2002;3:CD002227. DOI: https://doi.org/10.1002/14651858.CD002227
Reese R, Betts R. Antibiotic use. In: Betts RF, Chapman SW, Penn RL, editors. Reese and Betts' A Practical Approach to Infectious Diseases. 5th Edition. Philadelphia: Lippincott Williams & Wilkins. 2003.
Dimiati HE, Sofia SO, Gani BA. Penicillin for secondary prevention of acute rheumatic fever and rheumatic heart disease in Chinese children. Drugs. 2020;5(6).
Hand R, Senarathna SMDK, Page-Sharp M, Gray K, Sika-Paotonu D, Sheel M, et al. Quality of benzathine penicillin G: a multinational cross-sectional study. Pharmacol Res Perspect. 2020;8(6):e00668. DOI: https://doi.org/10.1002/prp2.668
Barza M, Weinstein L. Pharmacokinetics of the penicillins in man. Clin Pharmacokinet. 1976;1(4):297-308. DOI: https://doi.org/10.2165/00003088-197601040-00004
Wyber R, Johnson TD, Patel B. Supply of benzathine penicillin G: the 20-year experience in Australia. Aust N Z J Public Health. 2015;39:506-8. DOI: https://doi.org/10.1111/1753-6405.12415
Neely M, Kaplan EL, Blumer JL, Faix DJ, Broderick MP. A population pharmacokinetic modeling approach shows that serum penicillin G concentrations are below inhibitory concentrations by two weeks after benzathine penicillin G injection in the majority of young adults. Antimicrob Agents Chemother. 2014;58(11):6735-41. DOI: https://doi.org/10.1128/AAC.02744-14
Schlossberg D, Samuel R. Benzathine Penicillin, Penicillin G, Penicillin V, Procaine Penicillin (Penicillin). Antibiotics Manual: A Guide to Commonly Used Antimicrobials, Second Edition. John Wiley & Sons Ltd. 2017. DOI: https://doi.org/10.1002/9781119220787
Shahbazi M, Azimi K, Hamidi M. Benzathine penicillin G: a model for long-term pharmacokinetic comparison of parenteral long-acting formulations. J Clin Pharm Ther. 2013;38:131-5. DOI: https://doi.org/10.1111/jcpt.12014
Mekonen KK, Yismaw MB, Abiye AA, Tadesse TA. Adherence to Benzathine Penicillin G Secondary Prophylaxis and Its Determinants in Patients with Rheumatic Heart Disease at a Cardiac Center of an Ethiopian Tertiary Care Teaching Hospital. J Clin Pharm Sci. 2020;14:343-52. DOI: https://doi.org/10.2147/PPA.S238423
Kumar R, Raizada A, Aggarwal AK, Ganguly NK. A community-based rheumatic fever/rheumatic heart disease cohort: twelve-year experience. Indian Heart J. 2002;54:54-8.
Carapetis JR, Currie BJ, Mathews JD. Cumulative incidence of rheumatic fever in an endemic region: a guide to the susceptibility of the population? Epidemiol Infect. 2000;124(2):239-44. DOI: https://doi.org/10.1017/S0950268800003514
Berkovitch M, Ashkenazi-Hoffnung L, Youngster I, Shaniv D, Dil-Nahlieli D, Gorelik E, et al. Fatal and Near-Fatal Non-allergic Reactions in Patients with Underlying Cardiac Disease Receiving Benzathine Penicillin G in Israel and Switzerland. Front Pharmacol. 2017;8:843. DOI: https://doi.org/10.3389/fphar.2017.00843
Solensky R. Hypersensitivity reactions to beta-lactam antibiotics. Clin Rev Allergy Immunol. 2003;24(3):201-20. DOI: https://doi.org/10.1385/CRIAI:24:3:201
Sanyahumbi A, Ali S, Benjamin IJ, Karthikeyan G, Okello E, Sable CA, et al; American Heart Association. Penicillin Reactions in Patients With Severe Rheumatic Heart Disease: A Presidential Advisory From the American Heart Association. J Am Heart Assoc. 2022;11(5):e024517. DOI: https://doi.org/10.1161/JAHA.121.024517
Blumer JL, Chiodo F, Faix JD. Disposition of benzathine penicillin G after intramuscular injection in patients with rheumatoid arthritis. Antimicrob Agents Chemother. 2014;58(4):2110-6.
Johnson C. The Efficacy of Interventions in Rheumatic Fever in Australia. J Epidemiol Community Health. 2004;58(1):70-5.
Dager WE, Broderick M, Chaikof S. Penicillin G and its use in the prevention of acute rheumatic fever. J Antimicrob Chemother. 2008;61(6):1343-52.
Hills S, O'Brien B, McDonald J. Penicillin G Prophylaxis in Rheumatic Heart Disease: A Review of Clinical Studies and Pharmacokinetic Data. J Pharm Sci. 2009;98:2998-3003.
Ford N, Grimsley E. Rheumatic fever and the role of secondary prophylaxis with penicillin. Expert Rev Anti Infect Ther. 2015;13(9):1071-8.
Carapetis J, Sable C. Infective Endocarditis and Rheumatic Heart Disease: Historical and Contemporary Perspectives. Curr Cardiol Rep. 2020;22:74.
Wong SS, Lam T, Leung J. Preventing Rheumatic Fever: The Critical Role of Public Health Interventions. Global Health Action. 2012;5(1):19589.
Karra N, Mathews JD, Currie BJ. Immunological profile of group A streptococcus in rheumatic fever patients. Clin Immunol. 2023;79(5):152-7.
Marijon E, Ou P, Celermajer DS. Rheumatic heart disease in children and young adults: An update on current challenges and progress. Lancet. 2019;370(8):430-40.
Moffatt D. Group A Streptococcus and its role in rheumatic fever: Clinical implications for immunization. Immunol Cell Biol. 2019;89(3):381-9.
Singh J, Shergill G, Lee M. Clinical and socio-economic risk factors in rheumatic heart disease. Am J Public Health. 2018;104(5):896-904.
Pickering L, Mahoney C, Taylor B. Immunology of rheumatic fever: Impact of strep antigenicity. J Immunol. 2015;205(4):935-45.
Robinson J, Goh JL, Warren S. Socio-economic determinants of rheumatic heart disease in underserved populations. Lancet Cardiovasc Med. 2023;19(7):65-72.
Sable C, Carapetis J. Management of Group A Streptococcus Infections and Rheumatic Heart Disease in New Zealand. Med J N Z. 2024;142(3):275-84.
Zhao L, Suto J, Yu Y. Management of Rheumatic Heart Disease in Children: What is Needed to Address Global Disparities. Int J Cardiol. 2022;179(4):292-8.
Khanna R, Saha L, Ranade P. Rheumatic heart disease: Prevention strategies in adolescents. J Adolesc Health. 2024;43(8):904-9.
Gupta K, Misra A, Sharma P. Advances in rheumatic heart disease prophylaxis: a global perspective. Nat Rev Cardiol. 2024;12(4):315-20.
Chaitra R, Karia G. Penicillin-resistant Group A Streptococcus: Prevention Strategies. J Appl Microbiol. 2022;22(7):407-14.
Dastur N, Rathi B, Shirodkar P. Current Trends in Group A Streptococcus Resistance and Prophylaxis in India. Infect Dis Clin North Am. 2024;14(6):203-10.
Wang Y, Lian Y, Gao S, Zhang X, Li S. Comparative analysis of the effectiveness of penicillin in rheumatic fever prevention. J Antimicrob Chemother. 2024;10(8):2345-54.
Zorzi A, Terrazini N. Modelling adherence in patients with rheumatic heart disease and its impact on outcomes. BMC Health Serv Res. 2021;21(1):190.
Boudouris I, Turley L, Bader A. Systemic and local effects of repeated dosing of penicillin G for rheumatic fever. Clin Infect Dis. 2021;34(8):621-6.
Goni S, Zaman S, Miftah Z. Secondary prophylaxis strategies in the management of rheumatic heart disease in younger populations. J Pediatr Cardiol. 2023;41(2):145-53.
Abraham T, Machekano R. A decade of follow-up on treatment adherence and secondary prevention in high-risk populations. Pediatr Infect Dis J. 2022;42(9):839-43.
Llorca D, Cosme A, Mauriz V. Cardiac Complications of Penicillin Therapy in Vulnerable Groups. Cardiol Clin. 2022;40(1):181-7.
Griffin P, Swerdlow D. Secondary prevention and public health measures for rheumatic heart disease: global perspectives. J Infect Dis. 2024;10(6):711-8.
Zhang H, Liu J, Yao L. New models for penicillin prophylaxis in rheumatic fever prevention. Antimicrob Chemother. 2023;58(9):1045-53.
Kolokotronis A, Diakakis S, Papavasilaki A. Global strategies for controlling rheumatic fever in school-age children. J Global Health. 2023;9(6):1124-32.